Barclays Maintains Underweight on Zimmer Biomet Holdings, Lowers Price Target to $94

Barclays analyst Matt Miksic maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Underweight and lowers the price target from $100 to $94.